attovia therapeutics inc - ATTO
ATTO
Close Chg Chg %
14.50 -0.67 -4.62%
Closed Market
13.83
-0.67 (4.62%)
Volume: 330.73K
Last Updated:
Oct 23, 2026, 4:00 PM EDT
Company Overview: attovia therapeutics inc - ATTO
ATTO Key Data
| Open $14.36 | Day Range 13.53 - 14.75 |
| 52 Week Range N/A - N/A | Market Cap $647.33M |
| Shares Outstanding 45.65M | Public Float 28.44M |
| Beta N/A | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.52 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 455.92K |
ATTO Performance
| 1 Week | 0.73% | ||
| 1 Month | -22.22% | ||
| 3 Months | N/A | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
ATTO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About attovia therapeutics inc - ATTO
Attovia Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that creates next-generation biologic medicines for immune-mediated diseases. It was founded in 2022 and is headquartered in San Carlos, CA.
ATTO At a Glance
Attovia Therapeutics, Inc.
1091 Industrial Road
San Carlos, California 94070
| Phone | 1-510-399-5001 | Revenue | 1.35M | |
| Industry | Biotechnology | Net Income | -60,898,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATTO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ATTO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.011 |
ATTO Liquidity
| Current Ratio | 14.20 |
| Quick Ratio | 14.20 |
| Cash Ratio | 13.834 |
ATTO Profitability
| Gross Margin | 40.444 |
| Operating Margin | -4,974.741 |
| Pretax Margin | -4,490.889 |
| Net Margin | -4,510.963 |
| Return on Assets | -50.203 |
| Return on Equity | -57.203 |
| Return on Total Capital | -39.024 |
| Return on Invested Capital | -56.32 |
ATTO Capital Structure
| Total Debt to Total Equity | 3.49 |
| Total Debt to Total Capital | 3.372 |
| Total Debt to Total Assets | 3.172 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 2.141 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Attovia Therapeutics Inc - ATTO
Collapse All in section
| All values USD millions. | 2024 | 2025 | 5-year trend | ||
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | 1.35M | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | 313.00K | 804.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | 313.00K | 804.00K | - |
Depreciation
| - | - | 313.00K | 804.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | +156.87% | - |
Gross Income
| - | - | (313.00K) | 546.00K | - |
Gross Income Growth
| - | - | - | +274.44% | - |
Gross Profit Margin
| - | - | - | +40.44% | - |
| 2024 | 2025 | 5-year trend | |||
|---|---|---|---|---|---|
SG&A Expense
| - | - | 41.24M | 67.70M | - |
Research & Development
| - | - | 33.86M | 54.15M | - |
Other SG&A
| - | - | 7.38M | 13.55M | - |
SGA Growth
| - | - | - | +64.17% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 1.67M | 170.00K | - |
EBIT after Unusual Expense
| - | - | (43.23M) | (67.33M) | - |
Non Operating Income/Expense
| - | - | 3.43M | 6.70M | - |
Non-Operating Interest Income
| - | - | 3.44M | 6.63M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | - | (39.80M) | (60.63M) | - |
Pretax Income Growth
| - | - | - | -52.33% | - |
Pretax Margin
| - | - | - | -4,490.89% | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | (5.25M) | (271.00K) | - |
Consolidated Net Income
| - | - | (45.05M) | (60.90M) | - |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | - | (45.05M) | (60.90M) | - |
Net Income Growth
| - | - | - | -35.19% | - |
Net Margin Growth
| - | - | - | -4,510.96% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | - | (45.05M) | (60.90M) | - |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | - | (45.05M) | (60.90M) | - |
EPS (Basic)
| - | - | -0.9867 | -1.334 | - |
EPS (Basic) Growth
| - | - | - | -35.20% | - |
Basic Shares Outstanding
| - | - | 45.65M | 45.65M | - |
EPS (Diluted)
| - | - | -0.9867 | -1.334 | - |
EPS (Diluted) Growth
| - | - | - | -35.20% | - |
Diluted Shares Outstanding
| - | - | 45.65M | 45.65M | - |
EBITDA
| - | - | (41.24M) | (66.36M) | - |
EBITDA Growth
| - | - | - | -60.90% | - |
EBITDA Margin
| - | - | - | -4,915.19% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 45.25 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.494 | |
| FY Report Date | 12 / 2026 | Current Year's Estimate | -2.947 | |
| Last Quarter’s Earnings | -0.545 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | N/A | Next Fiscal Year Estimate | -2.167 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 1 | 4 | 4 |
| Mean Estimate | -0.49 | -0.44 | -2.95 | -2.17 |
| High Estimates | -0.36 | -0.44 | -2.07 | -1.76 |
| Low Estimate | -0.57 | -0.44 | -4.06 | -2.38 |
| Coefficient of Variance | -19.02 | N/A | -32.85 | -13.57 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | |
| OVERWEIGHT | 0 | 0 | |
| HOLD | 0 | 0 | |
| UNDERWEIGHT | 0 | 0 | |
| SELL | 0 | 0 | |
| MEAN | Buy | Buy |
SEC Filings for Attovia Therapeutics Inc - ATTO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Attovia Therapeutics Inc - ATTO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Steven Chan Chief Financial Officer | 140,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Oct 9, 2026 | Tao Fu President and CEO; Director | 538,300 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 76,295 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.11 per share | 1,686,882.45 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 64,337 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.05 per share | 1,418,630.85 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 64,537 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.78 per share | 1,405,615.86 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 64,980 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $20.84 per share | 1,354,183.20 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 65,280 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.05 per share | 1,439,424.00 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 66,320 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.84 per share | 1,448,428.80 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 67,500 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.02 per share | 1,486,350.00 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 67,900 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.03 per share | 1,495,837.00 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 74,870 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.02 per share | 1,648,637.40 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 75,542 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.97 per share | 1,659,657.74 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 76,395 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.55 per share | 1,646,312.25 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 76,875 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.1 per share | 1,698,937.50 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 77,075 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.02 per share | 1,697,191.50 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 80,477 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.06 per share | 1,775,322.62 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 82,033 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.05 per share | 1,808,827.65 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 82,233 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.03 per share | 1,811,592.99 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 83,565 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $21.87 per share | 1,827,566.55 |
| Sep 24, 2026 | Goldman Sachs & Co. LLC (Private Banking) | 84,012 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.03 per share | 1,850,784.36 |